Melanoma Diagnostics has been funded through a combination of private investments. To date, Dr. Kashani-Sabet's laboratory has been the recipient of several peer-reviewed grants to develop these biomarkers for melanoma. Melanoma Diagnostics is currently looking to partner with leaders in medical diagnostics to launch its proprietary technology worldwide. The company has several licensing and acquisition options for an exit strategy.